Belinostat: First global approval

Drugs

Volumn 74, Issue 13, 2014, Pages 1543-1554

  Poole, Raewyn M ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BELEODAQ; BELINOSTAT; CLN 9; DRUG THERAPY; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; LACTATE DEHYDROGENASE; PHARMACOLOGY; PX 105684; SULFONAMIDE; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; AREA UNDER THE CURVE; B CELL LYMPHOMA; CANCER OF UNKNOWN PRIMARY SITE; CHILL; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG DESIGN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG THERAPY; DYSPNEA; EPITHELIUM TUMOR; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; HYPOTENSION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CANCER; LIVER CELL CARCINOMA; LYMPHOMA, T-CELL, PERIPHERAL; MAXIMUM PLASMA CONCENTRATION; MESOTHELIOMA; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEOPLASM; NONHODGKIN LYMPHOMA; OVARY CANCER; PAIN; PATHOLOGY; PERIPHERAL EDEMA; PERIPHERAL T CELL LYMPHOMA; PERITONEUM CANCER; PHLEBITIS; PRURITUS; QT PROLONGATION; RASH; REVIEW; SOFT TISSUE CANCER; SOLID TUMOR; T CELL LYMPHOMA; THROMBOCYTOPENIA; THYMOMA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; UNITED STATES; VOMITING;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUG DESIGN; DRUG THERAPY; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, T-CELL, PERIPHERAL; PATHOLOGY; PHARMACOLOGY; SULFONAMIDES; THERAPEUTIC USE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84928774345     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0275-8     Document Type: Review

References (87)

1. Jacobsen ED. Pharmacotherapy of peripheral T-cell lymphoma: review of the latest clinical data. Clin Investig. 2013;3(7):665-79.
2. McDermott J, Jimeno A. Belinostat for the treatment of peripheral T-cell lymphomas. Drugs Today. 2014;50(5):337-45.
3. Vose J, Armitage J, Weisenburger D, et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-30.
4. Abouyabis AN, Shenoy PJ, Sinha R, et al. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011;2011:623924.
5. Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer. 2005;103(10):2091-8. (Pubitemid 40605117)
6. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970-6.
7. Lemoine M, Younes A. Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med. 2010;10(54):462-70.
8. Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell. 2002;108(4):475-87. (Pubitemid 34260873)
9. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev. 2004;18(19):2315-35. (Pubitemid 39310518)
10. Thiagalingam S, Cheng KH, Lee HJ, et al. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci. 2003;983:84-100. (Pubitemid 36399322)
11. Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs. 2009;69(14):1911-34.
12. Lindemann RK, Gabrielli B, Johnstone RW. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle. 2004;3(6):779-88. (Pubitemid 40187911)
13. Perez-Plasencia C, Duenas-Gonzalez A. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy? Mol Cancer. 2006;5:27.
14. Khabele D, Son DS, Parl AK, et al. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Cancer Biol Ther. 2007;6(5):795-801. (Pubitemid 47328364)
15. Candelaria M, Gallardo-Rincon D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol. 2007;18(9):1529-38. (Pubitemid 47365487)
16. Marquard L, Poulsen CB, Gjerdrum LM, et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology. 2009;54(6):688-98.
17. US Food and Drug Administration. FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma [media release]. 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403929.htm.
18. Spectrum Pharmaceuticals Inc. BELEODAQ® (belinostat): US prescribing information. 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/ 206256lbl.pdf. Accessed 18 July 2014.
19. US Food and Drug Administration. Belinostat. 2014. http://www.fda.gov/ drugs/informationondrugs/approveddrugs/ucm403960.htm. Accessed 15 July 2014.
20. TopoTarget A S. FDA grants acceptance to file and Priority Review for Beleodaq™ (belinostat) NDA in PTCL [media release]. 06 Feb 2014. http://investor.topotarget.com/releasedetail.cfm?ReleaseID=823721.
21. TopoTarget a S. FDA grants Orphan Drug status for belinostat for the treatment of Peripheral T-cell lymphoma (PTCL) [media release]. 9 Sept 2009. http://investor.topotarget.com/releasedetail.cfm?releaseid=531003.
22. TopoTarget A S. Belinostat gets EU Orphan Drug Designation for the treatment of peripheral T- cell lymphoma [media release]. 15 Oct 2012. http://www.topotarget.com.
23. TopoTarget A S. Belinostat gets European orphan drug designation for the treatment of malignant thymomas [media release]. 18 July 2013. http://www.topotarget.com.
24. TopoTarget A S. TopoTarget Successfully Buys Back Full Control of Belinostat [media release]. 22 Apr 2008. http://www.topotarget.com.
25. CuraGen Corporation, TopoTarget A S. CuraGen and TopoTarget Announce License and Collaboration Agreement for Development and Commercialization of Novel Phase I HDAC Inhibitor for Oncology [media release]. 3 June 2004. http://www.curagen.com.
26. Spectrum Pharmaceuticals Inc. Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial [media release]. 3 Feb 2010. http://www.sppirx.com.
27. TopoTarget A S, Spectrum Pharmaceuticals Inc. TopoTarget signs deal with potentional value of $US 350 million with Spectrum for dev. and commercialisation of Belinostat in North America and India [media release]. 2 Feb 2010. http://www.topotarget.com.
28. TopoTarget. Topotarget and Spectrum Pharmaceuticals agree on terms for commercial supply of belinostat [media release]. 07 Oct 2013. http://investor.topotarget.com/releasedetail.cfm?releaseid=795100.
29. CuraGen Corporation. CuraGen and TopoTarget Announce Cooperative Research and Development Agreement with the National Cancer Institute for PXD101 [media release]. 12 May 2005. http://www.curagen.com.
30. CuraGen Corporation. CuraGen and TopoTarget Announce Collaboration with the National Cancer Institute for the Clinical Development of PXD101 [media release]. 24 Aug 2004. http://www.curagen.com.
31. BioAlliance Pharma. The cross-border merger of bioalliance pharma and topotarget is legally effective as of 22 july 2014 - final calendar for trading on both euronext and nasdaq omx to be available soon [media release]. 23 July 2014. http://www.bioalliancepharma.com/en/fusion-transfrontaliere-de- bioalliance-pharma-topotarget-date-deffet-juridique-le-22-juillet-2014-le- calendrier-final-de-la-cotation-sur-euronext-nasdaq-omx-bientotdisponible/.
32. Qian X, Ara G, Mills E, et al. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer. 2008;122(6):1400-10. (Pubitemid 351287242)
33. Beck HC, Nielsen EC, Matthiesen R, et al. Quantitative proteomic analysis of post-translational modifications of human histones. Mol Cell Proteomics. 2006;5(7):1314-25. (Pubitemid 44103401)
34. Marquard L, Petersen KD, Persson M, et al. Monitoring the effect of belinostat in solid tumors by H4 acetylation. APMIS. 2008;116(5):382-92. (Pubitemid 351623872)
35. Chowdhury S, Howell GM, Teggart CA, et al. Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death. J Biol Chem. 2011;286(35):30937-48.
36. Buckley MT, Yoon J, Yee H, et al. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med. 2007;5:49.
37. Chan D, Zheng Y, Tyner JW, et al. Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer. J Cancer Res Clin Oncol. 2013;139(9):1507-14.
38. Lin SF, Lin JD, Chou TC, et al. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. PLoS One. 2013;8(10):e77684.
39. Dovzhanskiy DI, Arnold SM, Hackert T, et al. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer. BMC Cancer. 2012;12:226.
40. Gravina GL, Marampon F, Muzi P, et al. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer. Endocr Relat Cancer. 2013;20(3):321-37.
41. Gravina GL, Marampon F, Giusti I, et al. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. Int J Oncol. 2012;40(3):711-20.
42. Gravina GL, Marampon F. Belinostat potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, hsp90 and crm1 in preclinical models of prostate cancer. Anticancer Res. 2013;33(5):2257-8.
43. Hwang JJ, Kim YS, Kim MJ, et al. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells. J Urol. 2010;184(6):2557-64.
44. Li Y, Zhang B, Zhao H, et al. The effects of PXD101 on proliferation and apoptosis of human breast cell line MCF-7 and its mechanism. [Chinese]. Chin J Clin Oncol. 2012;39(5):249-53.
45. Ma BBY, Sung F, Tao Q, et al. The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs. 2010;28(2):107-14.
46. Na Y-S, Jung K-A, Kim S-M, et al. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models. Cancer Chemother Pharmacol. 2011;68(2):389-98.
47. Tumber A, Collins LS, Petersen KD, et al. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol. 2007;60(2):275-83. (Pubitemid 46742543)
48. Qian X, LaRochelle WJ, Ara G, et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther. 2006;5(8):2086-95. (Pubitemid 44336581)
49. Sudo M, Chin TM, Mori S, et al. Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer. Cancer Chemother Pharmacol. 2013;71(5):1325-34.
50. Duan J, Friedman J, Nottingham L, et al. Nuclear factor-kappa B p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2007;6(1):37-50. (Pubitemid 46206667)
51. Wang B, Wang X-b, Chen L-y, et al. Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis. Biochem Biophys Res Commun. 2013;437(1):1-6.
52. Spratlin JL, Pitts TM, Kulikowski GN, et al. Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Res. 2011;31(4):1093-103.
53. Sato A, Isono M, Ito K, et al. Bortezomib interacts synergistically with belinostat to cause ubiquitinated protein accumulation in renal cancer cells. J Urol. 2014;1:e373-e4.
54. Feng R, Oton A, Mapara MY, et al. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol. 2007;139(3):385-97. (Pubitemid 47512171)
55. Paoluzzi L, Scotto L, Marchi E, et al. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res. 2010;16(2):554-65.
56. Dai Y, Chen S, Kramer LB, et al. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res. 2008;14(2):549-58. (Pubitemid 351226125)
57. Dai Y, Chen S, Wang L, et al. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-B and Bim. Br J Haematol. 2011;153(2):222-35.
58. Steele NL, Plumb JA, Vidal L, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 2008;14(3):804-10. (Pubitemid 351231163)
59. Steele NL, Plumb JA, Vidal L, et al. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemother Pharmacol. 2011;67(6):1273-9.
60. Warren KE, McCully C, Dvinge H, et al. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates. Cancer Chemother Pharmacol. 2008;62(3):433-7. (Pubitemid 351871801)
61. Kiesel BF, Parise RA, Tjornelund J, et al. Quantitation of the HDAC inhibitor belinostat (PXD-101) and metabolites in human plasma by a novel LC-MS/MS assay. Cancer Res. 2012;72(8 Suppl 1):759.
62. Wang LZ, Ramirez J, Yeo W, et al. Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One. 2013;8(1):e54522.
63. Kiesel BP, R; Lin, Y; Allen, D; Reddy, G; Chawla, S, Piekarz, R; Ivy, P; et al, Pharmacokinetic analysis of the HDAC inhibitor belinostat (PXD-101) and metabolites in patients with hepatic dysfunction [abstract no. CT207]. In: American Association for Cancer Research Annual Meeting 2014: San Diego; 2014.
64. Agarwal N, Wade ML, Batten J, et al. Phase I study of histone deacetylase inhibitor belinostat in combination with warfarin in patients with solid tumors or hematological malignancies. Cancer Res. 2013;73(8 Suppl 1):1172.
65. O'Connor OA, Masszi T, Savage KJ, et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): results from the BELIEF trial. J Clin Oncol. 2013;31(15 Suppl. 1):8507.
66. Horwitz S, O'Connor O, Jurczak W, et al. Belinostat in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) subtype angioimmunoblastic T-cell lymphoma (AITL): results from the pivotal belief trial. Hematol Oncol. 2013;31:147-8.
67. Reimer P, Chawla S. Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma. J Hematol Oncol. 2013;6(1):69.
68. Persky DO, Bernstein SH, Goldman BH, et al. A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive B-cell lymphomas (rel/ref ABCL): SWOG S0520. J Clin Oncol (Meeting Abstracts). 2012;30(15 Suppl.):e18536.
69. Gimsing P, HansenM, Knudsen LM, et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol. 2008;81(3):170-6.
70. Holkova B, Bose P, Tombes MB, et al. Phase I trial of belinostat and bortezomib in patients with relapsed or refractory acute leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia in blast crisis - One year update. In: Blood Conference: 54th Annual Meeting of the American Society of Hematology, ASH. 2012;120(21).
71. Cashen A, Juckett M, Jumonville A, et al. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Ann Hematol. 2012;91(1):33-8.
72. Sullivan D, Singhal S, Schuster M, et al. A phase II study of PXD101 in advanced multiple myeloma. Blood. 2006;108(11):1023.
73. Yeo W, Chung HC, Chan SL, et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol. 2012;30(27):3361-7.
74. Ramalingam SS, Belani CP, Ruel C, et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2009;4(1):97-101.
75. Mackay HJ, Hirte H, Colgan T, et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer. 2010;46(9):1573-9.
76. Dizon DS, Damstrup L, Finkler NJ, et al. Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. Int J Gynecol Cancer. 2012;22(6):979-86.
77. Dizon DS, Blessing JA, Penson RT, et al. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;125(2):367-71.
78. Giaccone G, Rajan A, Berman A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol. 2011;29(15):2052-9.
79. Thomas A, Rajan A, Khozin S, et al. A phase (Ph) I/II study of belinostat (Bel) in combination with cisplatin, doxorubicin, and cyclophosphamide (PAC) in the first-line treatment of advanced or recurrent thymic malignancies. J Clin Oncol (Meeting Abstracts). 2012;30(15 Suppl.):7103.
80. Lassen U, Molife LR, Sorensen M, et al. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br J Cancer. 2010;103(1):12-7.
81. Luu TH, Frankel PH, Lim D, et al. Phase I trial of belinostat (PXD101) in combination with 13-cis-retinoic acid (13c-RA) in advanced solid tumor malignancies-a California Cancer Consortium NCI/CTEP sponsored trial [abstract no. Phi-53:(NCI# 7251)]. In: American Society of Clinical Oncology; 2013;
82. Balasubramaniam S, Bryla C, Redon CE, et al. Phase I trial of belinostat in combination with cisplatin (Cis) and etoposide (Etop). [abstract no. 2527]. In: American Society of Clinical Oncology; 2013.
83. Spectrum Pharmaceuticals Inc. Phase 1 dose finding study of belinostat for treatment of patients with peripheral T-cell lymphoma (PTCL) [ClinicalTrials.gov identifier NCT01839097], US National Institutes of Health, Clinicaltrials.gov. 2013. http://clinicaltrials.gov/ct2/show/NCT01839097?term= belinostat&rank=10. Accessed 15 July 2014.
84. University of Arizona. Belinostat and yttrium Y 90 ibritumomab tiuxetan in treating patients with relapsed aggressive B-cell nonhodgkin lymphoma [ClinicalTrials.gov identifier NCT01686165]; US National Institutes of Health, clinicaltrials.gov. 2012. http://clinicaltrials.gov/ct2/show/NCT01686165?term= belinostat&rank=15. Accessed 15 July 2014.
85. National Cancer Institute. A phase I study of belinostat in combination with cisplatin and etoposide in adults with small cell lung carcinoma and other advanced cancers [Clinicaltrials.gov identifier NCT00926640] US National Institutes of Health. Clinicaltrials.gov. 2009. http://clinicaltrials.gov/ct2/ show/NCT00926640?term=belinostat&rank=25. Accessed 15 July 2014.
86. National Cancer Institute. Belinostat for solid tumors and lymphomas in patients with varying degrees of hepatic dysfunction [Clinicaltrials.gov identifier NCT01273155] US National Institutes of Health, Clinicaltrials.gov. 2011. http://clinicaltrials.gov/ct2/show/NCT01273155?term=belinostat&rank= 26. Accessed 15 July 2014.
87. Massachusetts General Hospital. Carfilzomib plus belinostat in relapsed/refractory NHL [Clinicaltrials.gov identifier NCT02142530] US National Institutes of Health, Clinicaltrials.gov. 2014. http://clinicaltrials.gov/ct2/ show/NCT02142530?term=belinostat&rank=13. Accessed 15 July 2014.